Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease

Clinical Chemistry

Volumn 53, Issue 4, 2007, Pages 657-665

  Korolainen, Minna A ^a,b   Nyman, Tuula A ^c,d   Nyyssönen, Paula ^a,b   Hartikainen, E Samuel ^a,b   Pirttilä, Tuula ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; PREALBUMIN; PROTEIN; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; OXIDATION; PILOT STUDY; PROTEIN ANALYSIS; PROTEIN CARBONYLATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBROSPINAL FLUID PROTEINS; DATABASES, FACTUAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; ISOELECTRIC FOCUSING; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PILOT PROJECTS; PROTEIN CARBONYLATION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 34147221048     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.078014     Document Type: Article

References (40)

1. Navarro A, Sanchez Del Pino MJ, Gomez C, Peralta JL, Boveris A. Behavioral dysfunction, brain oxidative stress, and impaired mitochondrial electron transfer in aging mice. Am J Physiol Regul Integr Comp Physiol 2002;282:R985-92.
2. Navarro A, Emerit J, Edeas M, Bricaire F. Mitochondrial enzyme activities as biochemical markers of aging, neurodegenerative diseases and oxidative stress. Mol Aspects Med 2004;25:37-48.
3. Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 2005;827:65-75.
4. Pereira C, Agostinho P, Moreira PI, Cardoso SM, Oliveira CR. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord 2005;4:383-403.
5. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 2004;1000:1-7.
6. Mendoza-Núñez VM, Sánchez-Rodriguez MA, Retana-Ugalde R, Vargas-Guadarrama LA, Altamirano-Lozano MA. Total antioxidant levels, gender, and age as risk factors for DNA damage in lymphocytes of the elderly. Mech Ageing Dev 2001;122:835-47.
7. Schuessel K, Leutner S, Cairns NJ, Muller WE, Eckert A. Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J Neural Transm 2004;111:1167-82.
8. Liu H, Harrell LE, Shenvi S, Hagen T, Liu RM. Gender differences in glutathione metabolism in Alzheimer's disease. J Neurosci Res 2005;79:861-7.
9. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465-79.
10. Turner RS. Alzheimer's disease in man and transgenic mice: females at higher risk. Am J Pathol 2001;158:797-801.
11. Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, Copeland JR, et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings: the EURODEM-Prevalence Research Group. Ann Neurol 1991;30:381-90.
12. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med 2006;10:389-406.
13. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997;272:20313-6.
14. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, et al. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4- dinitrophenylhydrazine. J Histochem Cytochem 1998;46:731-5.
15. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994;233:346-57.
16. Görg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004;4:3665-85.
17. Mattila KM, Pirttilä T, Blennow K, Wallin A, Viitanen M, Frey H. Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol Scand 1994;89:192-8.
18. Choe LH, Dutt MJ, Relkin N, Lee KH. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 2002;23:2247-51.
19. Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L, Andreasen N, et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002;13:611-5.
20. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P, et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003;118:140-6.
21. Nakamura A, Goto S. Analysis of protein carbonyls with 2,4-dinitrophenyl hydrazine and its antibodies by immunoblot in two-dimensional gel electrophoresis. J Biochem (Tokyo) 1996;119:768-74.
22. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 2002;293:1566-70.
23. Yu HL, Chertkow HM, Bergman H, Schipper HM. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 2003;3:2240-8.
24. Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. Oxidative modifications and aggregation of Cu/Zn superoxide dismutase associated with Alzheimer's and Parkinson's diseases. J Biol Chem 2005;280:11648-55.
25. Korolainen MA, Goldsteins G, Nyman TA, Alafuzoff I, Koistinaho J, Pirttilä T. Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging 2006;27:42-53.
26. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF 3rd, Liotta LA. CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2005;2:57-70.
27. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001;310:173-86.
28. Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 1998;50:966-71.
29. Korolainen MA, Goldsteins G, Alafuzoff I, Koistinaho J, Pirttilä T. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis 2002;23:3428-33.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
31. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
32. Conrad CC, Choi J, Malakowsky CA, Talent JM, Dai R, Marshall P, et al. Identification of protein carbonyls after two-dimensional electrophoresis. Proteomics 2001;1:829-34.
33. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006;129:1177-87.
34. Hamidi Asl K, Liepnieks JJ, Nakamura M, Benson MD. Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol 1999;162:5556-60.
35. Schröder R, Linke RP. Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenic pattern. Virchows Arch 1999;434:551-60.
36. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunoperoxidase study. Acta Neuropathol (Berl) 1982;57:239-42.
37. Kametani F, Tanaka K, Sato M, Haga S, Saitoh T, Shinoda T, et al. A monoclonal antibody Hy20-54-16-3L to lambda (λ) light chain of human immunoglobulin reacts with amyloid in Alzheimer's disease brain. Neurosci Lett 1990;117:62-7.
38. Serot JM, Bene MC, Faure GC. Comparative immunohistochemical characteristics of human choroid plexus in vascular and Alzheimer's dementia. Hum Pathol 1994;25:1185-90.
39. You JS, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005;5:290-6.
40. Righetti PG, Castagna A, Antonucci F, Piubelli C, Cecconi D, Campostrini N, et al. Proteome analysis in the clinical chemistry laboratory: myth or reality? Clin Chim Acta 2005;357:123-39.